Lupin launches Mirabegron Extended-Release Tablets in the US

hanuman

Active member
FDA.jpg


Lupin announced the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, after having received approval from the United States Food and Drug Administration (USFDA).

Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 50 mg of Astellas Pharma Global Development. Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of $ 1,600 million in the US (IQVIA MAT July 2024).

The post appeared first on .
 
Top
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock